HemaSphere
(Jun 2022)
S267: PROPERDIN-BLOCKING ANTIBODIES ATTENUATE COMPLEMENT ALTERNATIVE PATHWAY ACTIVATION TRIGGERED BY CELL-FREE HEME IN SICKLE CELL DISEASE MODELS
- T. Trovati Maciel,
- R. Cofiell,
- C. Carvalho,
- S. Allali,
- R. Rignault,
- A. Bennet,
- Y. Dai,
- P. Tamburini,
- C. Gasteyger,
- O. Hermine,
- S. K. Kim
Affiliations
- T. Trovati Maciel
- 1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France
- R. Cofiell
- 2 Translational Research, Alexion AstraZeneca Rare Disease, New Haven, CT
- C. Carvalho
- 1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France
- S. Allali
- 1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France
- R. Rignault
- 1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France
- A. Bennet
- 3 Clinical Development and Translational Sciences, Alexion AstraZeneca Rare Disease, Boston, MA
- Y. Dai
- 3 Clinical Development and Translational Sciences, Alexion AstraZeneca Rare Disease, Boston, MA
- P. Tamburini
- 4 Research, Alexion AstraZeneca Rare Disease, New Haven, CT, United States of America
- C. Gasteyger
- 5 Clinical Development and Translational Sciences, Alexion AstraZeneca Rare Disease, Zurich, Switzerland
- O. Hermine
- 1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France
- S. K. Kim
- 2 Translational Research, Alexion AstraZeneca Rare Disease, New Haven, CT
- DOI
-
https://doi.org/10.1097/01.HS9.0000843960.95232.5f
- Journal volume & issue
-
Vol. 6
pp.
168
– 169
WeChat QR code